| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Matthew Baker, Colin Walsh |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 13.00p |
| Closing Price Change | -1.00p |
| % Change | 0.00 % |
| 52 Week High | 18.75 |
| 52 Week Low | 4.00 |
| Volume | 0 |
| Shares Issued | 113.66m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research